Major adverse cardiac and cerebrovascular events (MACCEs) in patients with acute ST-segment elevation myocardial infarction(STEMI) treated with pharmaco-invasive strategy with half–dose recombinant human prourokinase (PHDP): Two-year outcomes-Reference-Cited by-同舟云学术

Major adverse cardiac and cerebrovascular events (MACCEs) in patients with acute ST-segment elevation myocardial infarction(STEMI) treated with pharmaco-invasive strategy with half–dose recombinant human prourokinase (PHDP): Two-year outcomes

Published:2024-07 Issue:7 Volume:47 Page:3179-3180
ISSN:1015-9584
Container-title:Asian Journal of Surgery
language:en
Short-container-title:Asian Journal of Surgery

Author:

Yang Hui-Hui,Dou Jie,Liu Yong-Hua,Luo Dong-Lei^ORCID

Publisher

Elsevier BV

Reference4 articles.

1. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

2. STREAM-2 investigators. STREAM-2: half-dose tenecteplase or primary percutaneous coronary intervention in older patients with ST-segment-elevation myocardial infarction: a randomized, open-label trial;Van de Werf;Circulation,2023

3. Treatment of intravenous thrombolysis with half-dose recombinant human prourokinase reduces the rate of tirofiban use during early routine catheterization period;Jiang;Asian J Surg,2022

4. Pharmaco-invasive strategy with half-dose recombinant humanprourokinase(PHDP) study: one-year outcomes;Jiang;Asian J Surg,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comment on “Major adverse cardiac and cerebrovascular events (MACCEs) in patients with acute ST-segment elevation myocardial infarction(STEMI) treated with pharmaco-invasive strategy with half-dose recombinant human prourokinase (PHDP): Two-year outcomes ”;Asian Journal of Surgery;2024-08